Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 23;14(23):5758.
doi: 10.3390/cancers14235758.

Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy

Feifan Xiang  1   2   3 , Huipan Liu  3   4   5 , Jia Deng  3   4   5 , Wenzhe Ma  1 , Yue Chen  3   4   5
Affiliations
Review

Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy

Feifan Xiang et al. Cancers (Basel). .

Abstract

Giant cell tumor of bone (GCTB) is an aggressive non-cancerous bone tumor associated with risks of sarcoma and metastasis. Once malignancy occurs, the prognosis is generally poor. Surgery remains the main treatment for GCTB. Multidisciplinary management is a feasible option for patients wherein surgical resection is not an option or for those with serious surgery-related complications. Denosumab is an anti-nuclear factor kappa B ligand approved for the treatment of postmenopausal women with osteoporosis, bone metastases, and advanced or inoperable GCTB. However, the guidelines for treating GCTB are unclear; its short-term efficacy and safety in inoperable patients have been demonstrated. Lengthier therapies (high cumulative doses) or pre-operative adjuvant therapy may be associated with severe complications and high local recurrence rates. Short-term administration helps attain satisfactory local control and functionality. As a result, lately, the impact of different doses and lengths of treatment on the efficacy of denosumab in GCTB treatment, the incidence of complications, and recurrence rates have gained attention. The efficacy and safety of denosumab against GCTB, its impact on imaging assessment, related complications, and recurrence of GCTB were previously reviewed. For further research direction, this paper reviews the progress of studies evaluating the impact of the dose and duration of denosumab therapy for GCTB.

Keywords: denosumab; dose; duration of therapy; giant cell tumor of bone.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Patel S., Chiu R.G., Rosinski C.L., Ansari D., Chaker A.N., Nunna R.S., Behbahani M., Mehta A.I. Incidence, Management, and Outcomes of Spinal Giant Cell Tumor of Bone in Adult Patients: A National Cancer Database Analysis. World Neurosurg. 2020;144:e296–e305. doi: 10.1016/j.wneu.2020.08.135. - DOI - PubMed
    1. Choi J.H., Ro J.Y. The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv. Anat. Pathol. 2021;28:44–58. doi: 10.1097/PAP.0000000000000284. - DOI - PubMed
    1. Van der Heijden L., Dijkstra P.D.S., Blay J.Y., Gelderblom H. Giant cell tumour of bone in the denosumab era. Eur. J. Cancer. 2017;77:75–83. doi: 10.1016/j.ejca.2017.02.021. - DOI - PubMed
    1. Borkowska A., Goryń T., Pieńkowski A., Wągrodzki M., Jagiełło-Wieczorek E., Rogala P., Szacht M., Rutkowski P. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone. Oncol. Lett. 2016;12:4312–4318. doi: 10.3892/ol.2016.5246. - DOI - PMC - PubMed
    1. Fittall M.W., Lyskjaer I., Ellery P., Lombard P., Ijaz J., Strobl A.C., Oukrif D., Tarabichi M., Sill M., Koelsche C., et al. Drivers underpinning the malignant transformation of giant cell tumour of bone. J. Pathol. 2020;252:433–440. doi: 10.1002/path.5537. - DOI - PMC - PubMed